You are here: Welcome » Robby Nieuwlaat

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Both sides next revision
robby_nieuwlaat [2022/06/14 19:49]
liam [Canadian Stroke Prevention Intervention Network] 		robby_nieuwlaat [2022/06/14 20:38] (current)
liam [Funding]
Line 56: Line 56:
  
 Yet further research has been funded by [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Sanofi]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[Eucomed]], [[University of Basel]], and [[Marche Polytechnic University]].((Guerra, F., Brambatti, M., Nieuwlaat, R., Marcucci, M., Dudink, E., Crijns, H. J. G. M., Matassini, M. V., & Capucci, A. (2017). //Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey.// EP Europace, 19(12), 1922–1929. https://doi.org/10.1093/europace/eux205)) ((Allemann, S. S., Nieuwlaat, R., Navarro, T., Haynes, B., Hersberger, K. E., & Arnet, I. (2017). //Congruence between patient characteristics and interventions may partly explain medication adherence intervention effectiveness: an analysis of 190 randomized controlled trials from a Cochrane systematic review.// Journal of Clinical Epidemiology, 91, 70–79. https://doi.org/10.1016/j.jclinepi.2017.07.011)) ((Paquette, M., Riou França, L., Teutsch, C., Diener, H.-C., Lu, S., Dubner, S. J., Ma, C. S., Rothman, K. J., Zint, K., Halperin, J. L., Huisman, M. V., Lip, G. Y. H., & Nieuwlaat, R. (2017). //Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation.// Journal of the American College of Cardiology, 70(13), 1573–1583. https://doi.org/10.1016/j.jacc.2017.07.793)) Yet further research has been funded by [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Sanofi]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[Eucomed]], [[University of Basel]], and [[Marche Polytechnic University]].((Guerra, F., Brambatti, M., Nieuwlaat, R., Marcucci, M., Dudink, E., Crijns, H. J. G. M., Matassini, M. V., & Capucci, A. (2017). //Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey.// EP Europace, 19(12), 1922–1929. https://doi.org/10.1093/europace/eux205)) ((Allemann, S. S., Nieuwlaat, R., Navarro, T., Haynes, B., Hersberger, K. E., & Arnet, I. (2017). //Congruence between patient characteristics and interventions may partly explain medication adherence intervention effectiveness: an analysis of 190 randomized controlled trials from a Cochrane systematic review.// Journal of Clinical Epidemiology, 91, 70–79. https://doi.org/10.1016/j.jclinepi.2017.07.011)) ((Paquette, M., Riou França, L., Teutsch, C., Diener, H.-C., Lu, S., Dubner, S. J., Ma, C. S., Rothman, K. J., Zint, K., Halperin, J. L., Huisman, M. V., Lip, G. Y. H., & Nieuwlaat, R. (2017). //Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation.// Journal of the American College of Cardiology, 70(13), 1573–1583. https://doi.org/10.1016/j.jacc.2017.07.793))
 +
 +==== COVID-19 ====
 +
 +Nieuwlaat was lead author on a paper discussing [[antimicrobial resistance]] and [[COVID-19]] sponsored by the [[World Health Organization]].((Nieuwlaat, R., Mbuagbaw, L., Mertz, D., Burrows, L., Bowdish, D. M. E., Moja, L., Wright, G. D., & Schünemann, H. J. (2020). //COVID-19 and antimicrobial resistance: parallel and interacting health emergencies.// Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa773))
Back to top